JAK2 and B-cell chronic lymphocytic leukemia: Addition of JAK2, JAK1/2, or JAK3 specific inhibitors into the cell culture system significantly suppressed hyper phosphorylation of STAT5 in GIFT4-treated CLL cells (Fig. 3b).